Business Wire

Softomotive: Empowering Citizen Developers in Japan, South Korea and China Master RPA

16.12.2019 09:00:00 EET | Business Wire | Press release

Share

Softomotive, the fastest growing Robotic Process Automation (RPA) provider trusted by over 9000 clients globally, announces the localization of its comprehensive free online RPA training to meet the increasing demand of Softomotive’s RPA solutions across 3 new markets: Japan, South Korea and Greater China.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191215005029/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Softomotive expands Free online RPA training to 3 new markets: Japan, South Korea and Greater China. (Photo: Business Wire)

Together with the English version, Softomotive’s courses in RPA are now available in Japanese, Mandarin and Korean, with more local versions to come. WinAutomation users in Asia can now benefit from a more tailored experience and master RPA skills through the fully localized curriculum including the on-demand video courses, fact-sheets and quizzes.

“With the localized version of Softomotive’s RPA courses we are able to help even more developers and professionals master RPA skills covering Attended and UnAttended Automation.” says Marios Stavropoulos, Co-Founder and CEO for Softomotive. “By providing WinAutomation courses in Korean, Japanese, and Mandarin we are enabling the growth and adoption of RPA, making it much easier for organizations in those regions to train their employees as they seek to deploy and implement RPA”.

Continuing on its mission to improve the employability quotient of professionals and developers, Softomotive began working with channel partners who have both domain and linguistic expertise to improve the quality of the translations.

Several of our customers in South Korea and Japan also commented on the value of having localized courses on WinAutomation. One said that having Korean courses available is extremely helpful in educating employees and helping citizen developers start creating automations for the business much faster.

The official reveal of the localized courses was done in front of clients and partners in a series of events and meetings Seoul (South Korea), Tokyo (Japan) and Bengaluru (India). During these events, Softomotive’s leadership highlighted the role of Asia-Pacific region as one where RPA adoption is expected to see tremendous growth. The successful events and meetings served as a great platform to showcase how Softomotive’s People1st Approach to RPA, a bottom-up approach giving the power of automation to employees, is enabling businesses locally in South Korea, Japan and Greater China respond to the pressures of reduced labor productivity, following the recent regulations on working hours and work styles.

With the latest updates to the Softomotive Academy, learners from Japan, South Korea and China can obtain a Certification and Diploma in Robotic Process Automation.

Join

Entering the world of the Softomotive Academy is the first step to gaining credibility.

The online RPA learning portal provides an intuitive web-based interface that is accessible from any device (including mobile). Professionals can enroll and discover a rich catalogue of video-based RPA tutorials that support on-demand and self-paced learning on Attended and Unattended Automation.

Learn

Automation knowledge is fast becoming an essential skill set in the labor market.

The RPA Academy offers easy-to-follow individual courses helping learners to master RPA skills covering Attended and Unattended automation. Training ranges from a solid foundation on Robotic Desktop Automation (RDA) and enterprise RPA, to the development of complex process automation via scripting, and the advanced management and monitoring of software robots.

Grow

Receiving an Accreditation in Softomotive’s Process Automation solutions, learners become part of a global network of thousands of professionals already helping their respective organizations accelerate their digitization efforts. A Diploma in RPA enables professionals and developers stay ahead of the rest in this exciting industry. Learners can watch RPA courses at any time tailored for specific roles or can fully customize their learning experience based on their personal learning objectives.

Visit the Softomotive Academy to see the RPA courses in Japanese, Korean and Mandarin.

About Softomotive

Softomotive is one of the leading worldwide providers of Robotic Process Automation (RPA) solutions, trusted by more than 9,000 companies worldwide. Both attended and unattended RPA are delivered through powerful, robust RPA technology, from desktop installation to server-based software which is quick to deploy, easy to use and provides the best value for money

WinAutomation is the world’s best Robotic desktop automation (RDA) tool and provides a powerful, robust and easy to use Windows-based platform for building software robots.

ProcessRobot is a leading enterprise RPA platform, including enterprise grade security and controls, with links to best-of-breed AI technologies.

#ProcessRobot #Softomotive #WinAutomation

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information:
Jesus Kallergis
Softomotive Press Office
Email@ press@softomotive.com
Tel: +44 207 048 2000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye